Search Results - personalized+medicine

3 Results

Sort By:

SLCO1B3 Genotyping to Predict a Survival Prognosis of Prostate Cancer

Abstract: Steroid hormones have been implicated to play a fundamental role in the pathogenesis of prostate cancer. Polymorphisms in the genes that code for enzymes, or hormones involved in androgen regulatory pathway, reportedly influence risk for developing prostate cancer. Since many membrane transporters are modulators of steroid hormones absorption...

Published: 4/8/2024 | Inventor(s): William Figg, Alex Sparreboom, Douglas Price, Akinobu Hamada

Keywords(s): Androgen-directed Therapy, Biomarkers, diagnostic, Figg, genetic markers, Genomics, Hormone-Refractory, personalized medicine, predictive markers, prognostic, PROSTATE, SLCO1B3

Category(s): TherapeuticArea > Endocrinology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Diagnostics, TherapeuticArea > Oncology

IL7Rα-Specific Antibody for Treating Acute Lymphoblastic Leukemia (ALL)

Abstract: Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment. The...

Published: 4/8/2024 | Inventor(s): Scott Durum, Julie Hixon, Wenqing Li, Scotch Walsh, Lila Kashi

Keywords(s): Acute lymphoblastic leukemia (ALL), ANTIBODY, Antibody-Dependent Cellular Cytotoxicity (ADCC), Autoimmunity, CANCER, DIABETES, Durum, Interleukin-7 receptor-α (IL-7Rα), Multiple sclerosis, personalized medicine, Targeted therapy, THERAPY, TRANSPLANTATION

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration

Near-IR Light-Cleavable Antibody Conjugates and Conjugate Precursors

Abstract: This invention describes a general way to trigger the release of a bioactive small molecule from a targeting antibody. The key “trigger” is a fluorescent linker that is chemically disassembled upon irradiation with light in the near-IR range (~800 nm). This linker technology is a dramatic step forward for the field. The molecules can be tracked...

Published: 4/8/2024 | Inventor(s): Martin Schnermann, Alexander Gorka, Hisataka Kobayashi, Roger Nani

Keywords(s): ADC, Antibody-drug Conjugate, Chemical linkers, Fluorescent linker, PDT, personalized medicine, Photodynamic therapy, Targeted drug release, Targeted therapy

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics